Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis Report 2026

Report Coverage

The Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into non alcoholic fatty liver disease (NAFLD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non alcoholic fatty liver disease (NAFLD). The non alcoholic fatty liver disease (NAFLD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The non alcoholic fatty liver disease (NAFLD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with non alcoholic fatty liver disease (NAFLD) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non alcoholic fatty liver disease (NAFLD).

Read more about this report - Request a Free Sample

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Outlook

Non-alcoholic fatty liver disease (NAFLD) is a progressive metabolic liver disorder characterized by excessive fat accumulation in the liver unrelated to alcohol consumption. It arises primarily from obesity, insulin resistance, dyslipidemia, and sedentary lifestyles, and can advance to Nonalcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. As the condition progresses silently, many patients remain undiagnosed until significant liver damage has occurred.

The NAFLD treatment landscape is rapidly evolving, with therapies focused on improving metabolic function, reducing liver fat, and slowing or reversing fibrosis. Drug classes under investigation include thyroid hormone receptor-β agonists, GLP-1 receptor agonists, FGF analogues, anti-fibrotic agents, and metabolic modulators. In March 2024, Rezdiffra (resmetirom) became the first FDA-approved therapy for NASH with moderate to advanced fibrosis. This once-daily oral THR-β agonist demonstrated significant improvement in liver inflammation and fibrosis markers, marking a major milestone for the NAFLD/NASH drug pipeline and paving the way for expanded therapeutic innovation.

Non Alcoholic Fatty Liver Disease (NAFLD) Epidemiology

The NAFLD pipeline continues to grow in response to its rising global burden. According to 2021 data, adults aged 15–49 years experienced an incidence rate of 909.48 per 100,000 persons and a prevalence of 16,580.43 per 100,000 persons, reflecting its expanding impact on younger populations. Mortality reached 0.45 per 100,000 persons, while DALYs were 22.77 per 100,000 person-years, emphasizing the substantial health burden associated with the disease. These trends are closely linked to increasing rates of obesity, type 2 diabetes, and sedentary lifestyles worldwide. With no widely approved targeted therapy for early disease stages, the escalating prevalence underscores an urgent need for continued innovation in metabolic, anti-inflammatory, and anti-fibrotic treatments.

Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Therapeutic Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 22%, covers a major share of the total non alcoholic fatty liver disease (NAFLD) clinical trials. It is followed by phase I at 9%, and others. Strong representation across all phases indicates a robust pipeline, fostering innovation and potential new therapies that can enhance treatment options and market growth.

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the non alcoholic fatty liver disease (NAFLD) pipeline analysis include small molecules, polymers, peptides, gene therapy, and monoclonal antibody. The non alcoholic fatty liver disease (NAFLD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for non alcoholic fatty liver disease. For example, Semaglutide, a GLP-1 receptor agonist and peptide-based drug, is a prominent candidate under investigation for NAFLD and NASH. It works by enhancing insulin sensitivity, promoting weight loss, and reducing hepatic fat accumulation, which are key drivers of disease progression. Ongoing Phase 2 and Phase 3 studies are evaluating its potential to improve liver histology and metabolic outcomes while maintaining an established safety profile from its approved uses in diabetes and obesity.

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials – Key Players

The EMR report for the non alcoholic fatty liver disease (NAFLD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed non alcoholic fatty liver disease (NAFLD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in non alcoholic fatty liver disease (NAFLD) clinical trials:

• Madrigal Pharmaceuticals, Inc.
• Ain Shams University
• The University of Texas Health Science Center
• Akero Therapeutics, Inc.
• Novo Nordisk A/S
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• GlaxoSmithKline
• Hepion Pharmaceuticals, Inc.
• Tasly Biopharmaceuticals Co., Ltd.
• 1Globe Health Institute
• Seoul National University Hospital
• Boehringer Ingelheim

Non Alcoholic Fatty Liver Disease (NAFLD) – Emerging Drugs Profile

Key Questions Answered in the Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight Report

• Which companies/institutions are leading the non alcoholic fatty liver disease (NAFLD) drug development?
• What is the efficacy and safety profile of non alcoholic fatty liver disease (NAFLD) pipeline drugs?
• Which company is leading the non alcoholic fatty liver disease (NAFLD) pipeline development activities?
• What is the current non alcoholic fatty liver disease (NAFLD) commercial assessment?
• What are the opportunities and challenges present in the non alcoholic fatty liver disease (NAFLD) pipeline landscape?
• What is the efficacy and safety profile of non alcoholic fatty liver disease (NAFLD) pipeline drugs?
• Which company is conducting major trials for non alcoholic fatty liver disease (NAFLD) drugs?
• Which companies/institutions are involved in non alcoholic fatty liver disease (NAFLD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in non alcoholic fatty liver disease (NAFLD)?

Reasons To Buy This Report

The Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non alcoholic fatty liver disease (NAFLD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into non alcoholic fatty liver disease (NAFLD) collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast

Liver Health Supplements Market